Animal and human studies with the mitochondria-targeted antioxidant MitoQ.
As mitochondrial oxidative damage contributes to a wide range of human diseases, antioxidants designed to be accumulated by mitochondria in vivo have been developed. The most extensively studied of these mitochondria-targeted antioxidants is MitoQ, which contains the antioxidant quinone moiety covalently attached to a lipophilic triphenylphosphonium cation. MitoQ has now been used in a range of in vivo studies in rats and mice and in two phase II human trials. Here, we review what has been learned from these animal and human studies with MitoQ.
Smith
Robin A J
RA
Department of Chemistry, University of Otago, Dunedin, New Zealand.
Murphy
Michael P
MP
D000284:Administration, Oral; D000818:Animals; D000975:Antioxidants / Q000378:metabolism / Q000494:pharmacology*; D002412:Cations; D017322:Clinical Trials, Phase II as Topic; D004195:Disease Models, Animal; D005234:Fatty Liver / Q000628:therapy; D006801:Humans; D008107:Liver Diseases / Q000473:pathology; D051379:Mice; D008928:Mitochondria / Q000378:metabolism; D009943:Organophosphorus Compounds / Q000494:pharmacology*; D018384:Oxidative Stress; D051381:Rats; D016896:Treatment Outcome; D014451:Ubiquinone / Q000031:analogs & derivatives* / Q000494:pharmacology
D000975:Antioxidants; D002412:Cations; D009943:Organophosphorus Compounds; D014451:Ubiquinone; C429014:mitoquinone